Ainos, Inc.
Ainos, Inc.
Your view on AIMDW
Overview
What the company does, where it operates, and who runs it.
About Ainos, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chun-Hsien Tsai
- Headquarters
- 3050 Post Oak Boulevard, Houston, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chun-Hsien Tsai
- Headquarters
- 3050 Post Oak Boulevard, Houston, TX, US
Ainos, Inc. operates as a healthcare enterprise dedicated to advancing medical technologies. Its core focus involves developing both point-of-care diagnostic solutions and innovative, safe therapeutic options for various health conditions. The company's offerings include a COVID-19 antigen rapid test kit.
This is complemented by the Ainos' cloud-based test management App, a holistic platform comprising the rapid test kit, a personal mobile application, and an enterprise-level app. Ainos also provides a COVID-19 nucleic acid test.
Further technologies under development or offered include point-of-care testing for volatile organic compounds and Very Low-Dose Oral Interferon Alpha, an oral formulation of IFN-a with broad therapeutic potential. The firm is additionally developing a Synthetic RNA (SRNA) technology platform, with specific work being conducted in Taiwan.
Beyond these, Ainos' product line extends to women's health, pneumonia, the Ainos Pen, AI Nose, and a variety of other products. Originally incorporated in 1984, the company was formerly known as Amarillo Biosciences, Inc. and rebranded to Ainos, Inc. in May 2021. Its main operations are based in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Ainos, Inc., and the rating behind it. AIMDW last traded at $0.06; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Ainos, Inc.. Starting points for Ainos, Inc.: EPS -$1.96, beta 2.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Ainos, Inc.. Ainos, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Ainos, Inc.. Trailing twelve-month EPS for Ainos, Inc. stands at -$1.96. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Ainos, Inc.. Ainos, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Ainos, Inc. valued side by side against its closest peers. Ainos, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Ainos, Inc., and how their positions are changing. At a $2.9M market value, institutional positions materially move Ainos, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Ainos, Inc. executives and directors. Shares of Ainos, Inc. have traded between $0.10 and $0.17 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Ainos, Inc.. Ainos, Inc. is a $2.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Ainos, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Ainos, Inc.. Coverage tracks Ainos, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.